N-(3-acetyl-4-chlorophenyl)methanesulfonamide | 372093-06-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-(3-acetyl-4-chlorophenyl)methanesulfonamide
• CAS: 372093-06-6
• 化学式: C₉H₁₀ClNO₃S
• 分子量: 247.702
• InChiKey: SCFGILXELSGUIF-UHFFFAOYSA-N

物化性质

• 沸点：
  363.7±52.0 °C(Predicted)
• 密度：
  1.428±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-acetyl-4-chlorophenyl)methanesulfonamide 在 溴 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 N-(3-Bromoacetyl-4-chlorophenyl)methanesulfonamide
  参考文献：
  名称：

  BICYCLIC COMPOUND

  摘要：

  公开号：

  EP1447400B1
• 作为产物：
  描述：

  甲基磺酰氯 、 2-氯-5-氨基苯乙酮 在 吡啶 作用下， 以 水 、 甲苯 为溶剂， 生成 N-(3-acetyl-4-chlorophenyl)methanesulfonamide
  参考文献：
  名称：

  Novel bicyclic compounds

  摘要：

  通式（I）的化合物：1或其盐，其中R1是氢、羟基或卤素；R2是NHSO2CH3、SO2NHCH3或类似物；R5和R6各自独立地是氢、C1-6烷基、可选择取代的苯基或可选择取代的苄基；X是NH、硫、氧或亚甲基；Y是氧、NR7、硫、亚甲基或键；*代表一个不对称的碳原子。这些化合物可用作治疗或预防糖尿病、肥胖症、高脂血症、消化系统疾病、抑郁症或尿路紊乱的药物。

  公开号：

  US20030191174A1

文献信息

• Novel bicyclic compounds
  申请人：——

  公开号：US20030191174A1

  公开（公告）日：2003-10-09

  Compounds of the general formula (I): 1 or a salt thereof, wherein R 1 is hydrogen, hydroxyl or halogen; R 2 is NHSO 2 CH 3 , SO 2 NHCH 3 or the like; R 5 and R 6 each independently is hydrogen, C 1-6 alkyl, optionally substituted phenyl or optionally substituted benzyl; X is NH, sulfur, oxygen or methylene; Y is oxygen, NR 7 , sulfur, methylene or a bond; and * represents an asymmetric carbon atom. The compounds are useful as a medicine for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances.

  通式（I）的化合物：1或其盐，其中R1是氢、羟基或卤素；R2是NHSO2CH3、SO2NHCH3或类似物；R5和R6各自独立地是氢、C1-6烷基、可选择取代的苯基或可选择取代的苄基；X是NH、硫、氧或亚甲基；Y是氧、NR7、硫、亚甲基或键；*代表一个不对称的碳原子。这些化合物可用作治疗或预防糖尿病、肥胖症、高脂血症、消化系统疾病、抑郁症或尿路紊乱的药物。
• Bicyclic compound
  申请人：Miyoshi Shiro

  公开号：US20050020602A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R 2 represents NHSO 2 R 3 , etc., provided that R 3 represents C 1-6 alkyl, etc. R 5 represents hydrogen, etc. R 6 and R 7 may be the same or different and each independently represents hydrogen, etc. X represents oxygen, etc. Y represents oxygen, etc. Z 1 to Z 6 each represents carbon, etc. n is an integer of 0 to 6 and ast1 indicates that the carbon atom is asymmetric, and *2, in the case where R 5 is not hydrogen, indicates that the carbon atom is asymmetric or a salt of the compound.

  化合物的通式为I：I，其中R1代表氢等，R2代表NHSO2R3等，但R3代表C1-6烷基等，R5代表氢等，R6和R7可以相同也可以不同，且各自独立地代表氢等，X代表氧等，Y代表氧等，Z1至Z6各自代表碳等，n为0至6的整数，ast1表示碳原子是不对称的，*2表示当R5不是氢时，碳原子是不对称的或化合物的盐。
• Indole compounds as B3 androceptor agonist
  申请人：Miyoshi Shiro

  公开号：US20080076815A1

  公开（公告）日：2008-03-27

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式(I)的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是(C1-C6)烷基或类似物；R5是氢原子或类似物；R6和R7可以相同或不同，且各自独立地是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1至Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• Indazole compounds as β3 adrenoceptor agonist
  申请人：Asahi Kasei Pharma Corporation

  公开号：US07271190B2

  公开（公告）日：2007-09-18

  A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R2 represents NHSO2R3, etc., provided that R3 represents C1-6 alkyl, etc. R5 represents hydrogen, etc. R6 and R7 may be the same or different and each independently represents hydrogen, etc. X represents oxygen, etc. Y represents oxygen, etc. Z1 to Z6 each represents carbon, etc. n is an integer of 0 to 6 and ast1 indicates that the carbon atom is asymmetric, and *2, in the case where R5 is not hydrogen, indicates that the carbon atom is asymmetric or a salt of the compound.

  化合物由一般式I表示：其中R1代表氢等，R2代表NHSO2R3等，但要求R3代表C1-6烷基等，R5代表氢等，R6和R7可以相同也可以不同，分别独立地代表氢等，X代表氧等，Y代表氧等，Z1至Z6各自代表碳等，n是0至6的整数，ast1表示该碳原子是不对称的，而*2，在R5不是氢的情况下，表示该碳原子是不对称的或该化合物的盐。
• Bicyclic compounds
  申请人：Ikuta Shunichi

  公开号：US06861444B2

  公开（公告）日：2005-03-01

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is hydrogen, hydroxyl or halogen; R 2 is NHSO 2 CH 3 , SO 2 NHCH 3 or the like; R 5 and R 6 each independently is hydrogen, C 1-6 alkyl, optionally substituted phenyl or optionally substituted benzyl; X is NH, sulfur, oxygen or methylene; Y is oxygen, NR 7 , sulfur, methylene or a bond; and * represents an asymmetric carbon atom. The compounds are useful as a medicine for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances.

  通式（I）的化合物或其盐，其中R1为氢、羟基或卤素；R2为NHSO2CH3、SO2NHCH3或类似物；R5和R6各自独立地为氢、C1-6烷基、可选取代的苯基或可选取代的苄基；X为NH、硫、氧或亚甲基；Y为氧、NR7、硫、亚甲基或键；*代表不对称的碳原子。这些化合物可用作治疗或预防糖尿病、肥胖症、高脂血症、消化系统疾病、抑郁症或尿路障碍的药物。